Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study)

Most axSpA patients treated with IXE had long-standing, highly active disease involving multiple domains and prior multiple domains and prior b/tsDMARDs (b/tsDMARD) exposure. Despite this, half remained on IXE at 1 year with improved disease activity, highlighting its potential as a treatment option in daily practice.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-01-09
DOI
https://doi.org/10.3389/fmed.2025.1704081
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study)

Francisco Pérez-Sádaba, Victoria Navarro-Compán, Clara Pérez-Rambla, Itxaso Aguirregabiria et al.
Frontiers in Medicine
Spondyloarthritis Studies and Treatments
article

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study)

Francisco Pérez-Sádaba, Victoria Navarro-Compán, Clara Pérez-Rambla, Itxaso Aguirregabiria, Ma Concepción Fito-Manteca, Cristina Valero-Martínez, Sara García-Carazo, Raquel Almodóvar, Cristina Campos, Silvia Díaz-Cerezo, Amelia Cobo
article en

Abstract

Most axSpA patients treated with IXE had long-standing, highly active disease involving multiple domains and prior multiple domains and prior b/tsDMARDs (b/tsDMARD) exposure. Despite this, half remained on IXE at 1 year with improved disease activity, highlighting its potential as a treatment option in daily practice.

Frontiers in MedicineVol. 12
Hospital Universitario Fundación Alcorcón (ES), Ayuntamiento de Castellón de la Plana (ES), Hospital General Universitario De Valencia (ES), Eli Lilly (Spain) (ES), Hospital Universitario de La Princesa (ES), Universidad de Navarra (ES)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 95%
Spondyloarthritis Studies and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study) — Francisco Pérez-Sádaba, Victoria Navarro-Compán, et al. · Frontiers in Medicine (2026) | TGRS Research Map | TGRS